Citius Oncology, Inc. Common Stock (CTOR)

• Market cap: $154M
• 1 day: 3.70%
• 5 days: 15.29%
• 1 month: 4.81%
• 3 months: 120.22%
• 6 months: 66.10%
• Year to date: 64.71%
• 1 year: -3.92%
• 5 years: -80.57%
• 10 years: -80.57%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

890% more capital invested

Capital invested by funds: $97.7K [Q1] → $967K (+$869K) [Q2]

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

17% more funds holding

Funds holding: 6 [Q1] → 7 (+1) [Q2]

0.16% more ownership

Funds ownership: 0.15% [Q1] → 0.31% (+0.16%) [Q2]